BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to BioQuest third quarter 2025 earnings conference call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touchtone phone. To withdraw a question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Nick Wilder. Please go ahead. Good morning, and welcome to Biochrist's third quarter 2025 corporate update and financial results conference call. Participating with me today are CEO John Stonehouse, President and Chief Commercial Officer Charlie Geyer, Chief Development Officer Dr. Bill Sheridan, and Chief Financial Officer Bob Erguiaz. A press release and slide presentation about today's news are available on our Investor Relations website. Today's call may contain forward-looking statements, including statements regarding future financial results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risk. and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide two of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release....